血小板丰富的血蛋白作为口腔平坦的治疗方案:基于证据的系统审查
相关实验视频
Updated: Jul 27, 2025
05:57
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
4.2K
Nisha Maddheshiya1, Adit Srivastava1, Varun Rastogi2
1Department of Oral Medicine and Radiology, Faculty of Dental Sciences, I.M.S, B.H.U, Azamgarh, Uttar Pradesh, India.
National journal of maxillofacial surgery
|June 5, 2023
概括
富血小板血 (PRP) 显示出治疗口腔平坦 (OLP) 的前景,这是一种自身免疫性疾病. 这种疗法可以改善不响应OLP病例的疼痛和病变外观.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 再生医学是一种再生医学.
背景情况:
- 口腔平斑 (OLP) 是一种自身免疫性疾病,影响患者的生活质量.
- 目前的OLP治疗方法各不相同,并且由于疾病耐药性和复发性,往往不足.
- 富血小板血 (PRP) 正成为一种具有成本效益和低风险的治疗选择.
研究的目的:
- 系统地审查富血小板血 (PRP) 在治疗口腔平 (OLP) 的疗效.
- 评估PRP作为不响应OLP病例的潜在替代疗法.
主要方法:
- 一个系统的审查的文章从PubMed/Medline,Scopus,和科学网络.
- 使用Cochrane偏差风险工具和Joanna Briggs研究所进行的包括临床研究和病例报告的质量评估.
- 包括4篇文章:2项临床试验和2个病例报告,所有这些都涉及侵蚀性OLP.
主要成果:
- 富血小板血 (PRP) 在改善疼痛和病变外观方面显示出显著的治疗益处.
- 在没有对常规疗法反应的患者的病例报告中,使用PRP.
- 所有审查的病例都属于侵蚀性OLP亚型.
结论:
- 富血小板血 (PRP) 可以被视为一种潜在的替代疗法,用于管理不响应的口腔状平原 (OLP).
- 建议进行进一步的研究,以确定关于OLP的PRP疗效的最终结论.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
223
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
223
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
569
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
569